MAREDY SAR: Open Payments
NPI 1598368045 · LYNN, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,831 in 82 payments from 14 companies in 2025. Trend: 2023 $81 · 2024 $621 · 2025 $1,831
Food & beverage: $1,831
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 28 | $731 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $185 |
| Lilly USA, LLC | 11 | $174 |
| Sumitomo Pharma America, Inc. | 8 | $147 |
| Otsuka America Pharmaceutical, Inc. | 6 | $119 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $108 |
| PFIZER INC. | 5 | $99 |
| Lundbeck LLC | 3 | $60 |
| Exact Sciences Corporation | 2 | $57 |
| Amgen Inc. | 2 | $53 |
Products named: FARXIGA, JARDIANCE, AIRSUPRA, REXULTI, GEMTESA, Kerendia, PREVNAR 20, BREZTRI.
Industry payments across MA — which companies pay providers there.
